Second, sensitive and specific biomarkers had to be developed (CSF amyloid and tau, amyloid PET tracers) to determine which patients with MCI or clinical AD had true AD pathology and to evaluate whether anti-amyloid treatments effectively cleared amyloid from the brain. This evidence concerns the gene MAPT and Alzheimer disease.